Texas Oncology, Dallas, TX 75246, USA.
McKesson Life Sciences, The Woodlands, TX 77380, USA.
Future Oncol. 2020 Aug;16(22):1575-1584. doi: 10.2217/fon-2020-0280. Epub 2020 Jun 4.
To evaluate the real-world impact of brain metastases (BM) among patients with mutation-positive (m) metastatic non-small-cell lung cancer (NSCLC). This retrospective, observational matched cohort electronic health record study assessed adults with m metastatic NSCLC with/without BM. Among 402 patients split equally between both cohorts (±BM), the majority were Caucasian (69%), female (65%) and with adenocarcinoma (92%). Overall symptom burden and ancillary support service use were higher and median overall survival from metastatic diagnosis was significantly shorter in BM patients (11.9 vs 16 months; p = 0.017). BM in m NSCLC patients can negatively impact clinical outcomes. New targeted therapies that can penetrate the blood-brain barrier should be considered for treating these patients.
评估突变阳性（m）转移性非小细胞肺癌（NSCLC）患者脑转移（BM）的实际影响。本回顾性、观察性匹配队列电子健康记录研究评估了伴有/不伴有 BM 的 m 转移性 NSCLC 成年患者。在 402 名患者中，两组（±BM）各有 201 名，大多数为白种人（69%），女性（65%），且为腺癌（92%）。BM 患者的整体症状负担和辅助支持服务使用率较高，且从转移性诊断开始的中位总生存期明显更短（11.9 个月 vs 16 个月；p = 0.017）。m NSCLC 患者的 BM 可能对临床结局产生负面影响。对于这些患者，应考虑使用可穿透血脑屏障的新型靶向疗法。
